<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02926066</url>
  </required_header>
  <id_info>
    <org_study_id>201511036MIND</org_study_id>
    <nct_id>NCT02926066</nct_id>
  </id_info>
  <brief_title>A Clinical Trial for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC - An Expansion</brief_title>
  <official_title>A Clinical Trial for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC - An Expansion (NTUH-AADC-011)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial expansion is to offer patients, who are not enrolled into the Phase I/II
      trial, a chance of treatment, to extend the experience in this gene therapy, and to increase
      the dosage slightly to waive the drug dilution procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AAV2-hAADC will be made by a GMP laboratory. An MRI will be performed to define the brain
      structure, and then metal nails will be fixed on the skull and a CT will be performed. The
      two images will be confined and the direction and depth of infusion will be determined.
      During the surgery, a stereotactic device will be implanted on both sides of the brain on a
      bur hole. Each putamen will be injected for two times. If there is no complication from the
      surgery, the patients will enter the follow up period.

      In Cohort 1, for patients designing to have high dose (2.37x10^11 vg), sequential enrollment
      will be applied. The patients need to be followed for 2 months or more until the severity of
      post-gene therapy dyskinesia decreases, judged by a decrease in dose of drugs used to
      decrease dyskinesia or an improvement in feeding. After the agreement of the Safety
      Committee, the next high-dose patient can be enrolled. In Cohort 2, only patients older than
      or equal to 3 years need sequential enrollment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase of neurotransmitter metabolite HVA or HIAA levels in CSF one year after gene therapy. (Progress compare with baseline)</measure>
    <time_frame>13 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Increase more than 10 points score of PDMS-II compare with baseline.</measure>
    <time_frame>13 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-surgery intracerebral hemorrhage didn't happen.</measure>
    <time_frame>13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-surgery CSF leakage of Craniotomy</measure>
    <time_frame>13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of dyskinesia post-gene therapy (if NG tube feeding is required)</measure>
    <time_frame>13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4. Incidence of other SAE (we will collect all AEs and their severity information, including treatment-emergent adverse events)</measure>
    <time_frame>13 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Aromatic Amino Acid Decarboxylase Deficiency</condition>
  <arm_group>
    <arm_group_label>AAV2-hAADC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage form: Aqueous solutionDose(s): 2.371x1011 vg/case Dosing schedule: Intracerebral infusion, single doseMechanism of action (if known): supplement a gene defect</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AAV2-hAADC</intervention_name>
    <description>Dosage form: Aqueous solutionDose(s): 2.371x1011 vg/case Dosing schedule: Intracerebral infusion, single doseMechanism of action (if known): supplement a gene defect</description>
    <arm_group_label>AAV2-hAADC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A definitive diagnosis of AADC deficiency, such as a CSF study showing decreased
             levels of HVA, 5-HIAA, an elevated L-DOPA level or the presence of at least one AADC
             gene pathologic mutation etc.

          2. Typical clinical manifestations of the disease, such as oculogyric crisis, hypotonia
             and delayed development.

          3. Over 2 years of age, or having adequate skull thickness for surgery.

          4. The patient must not older than 72 months of age before gene therapy.

          5. Participating patient must be fully cooperative for assessments and tests conducted
             before and throughout the entire trial.

          6. The parents or guardians must sign the Informed Consent Form to give their consent.

        Exclusion criteria

          1. Obvious brain structural change in the judgment of the investigator.

          2. The subject will be excluded if there is any health or neurological concern which
             might increase the risk of surgery. The principal investigator has the right to assess
             whether the subject is eligible for this trial based on the subject's health
             condition.

          3. Patients with anti-AAV2 antibody titer higher than 1,200, or &gt;1 O.D. value by ELISA
             will be excluded.

          4. Subject participating in this trial must not take any drug that might compromise this
             clinical trial; except that the drugs mentioned in the protocol can be used for a
             specified period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yin-Hsiu Chien, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yin-Hsiu Chien, Doctor</last_name>
    <phone>+886 2 23123456</phone>
    <phone_ext>71937</phone_ext>
    <email>chienyh@ntu.edu.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wuh-Liang Hwu, Doctor</last_name>
    <phone>+886 2 23123456</phone>
    <phone_ext>71938</phone_ext>
    <email>hwuwlntu@ntu.edu.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yin-Hsiu Chien, Doctor</last_name>
      <phone>+886 2 23123456</phone>
      <phone_ext>71937</phone_ext>
      <email>chienyh@ntu.edu.tw</email>
    </contact>
    <contact_backup>
      <last_name>Wuh-Liang Hwu, Doctor</last_name>
      <phone>+886 2 23123456</phone>
      <phone_ext>71938</phone_ext>
      <email>hwuwlntu@ntu.edu.tw</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Abeling NG, van Gennip AH, Barth PG, van Cruchten A, Westra M, Wijburg FA. Aromatic L-amino acid decarboxylase deficiency: a new case with a mild clinical presentation and unexpected laboratory findings. J Inherit Metab Dis. 1998 Jun;21(3):240-2.</citation>
    <PMID>9686366</PMID>
  </reference>
  <reference>
    <citation>Afione SA, Conrad CK, Kearns WG, Chunduru S, Adams R, Reynolds TC, Guggino WB, Cutting GR, Carter BJ, Flotte TR. In vivo model of adeno-associated virus vector persistence and rescue. J Virol. 1996 May;70(5):3235-41.</citation>
    <PMID>8627804</PMID>
  </reference>
  <reference>
    <citation>Auricchio A, Hildinger M, O'Connor E, Gao GP, Wilson JM. Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum Gene Ther. 2001 Jan 1;12(1):71-6.</citation>
    <PMID>11177544</PMID>
  </reference>
  <reference>
    <citation>Bainbridge JW, Mehat MS, Sundaram V, Robbie SJ, Barker SE, Ripamonti C, Georgiadis A, Mowat FM, Beattie SG, Gardner PJ, Feathers KL, Luong VA, Yzer S, Balaggan K, Viswanathan A, de Ravel TJ, Casteels I, Holder GE, Tyler N, Fitzke FW, Weleber RG, Nardini M, Moore AT, Thompson DA, Petersen-Jones SM, Michaelides M, van den Born LI, Stockman A, Smith AJ, Rubin G, Ali RR. Long-term effect of gene therapy on Leber's congenital amaurosis. N Engl J Med. 2015 May 14;372(20):1887-97. doi: 10.1056/NEJMoa1414221. Epub 2015 May 4.</citation>
    <PMID>25938638</PMID>
  </reference>
  <reference>
    <citation>Bankiewicz KS, Eberling JL, Kohutnicka M, Jagust W, Pivirotto P, Bringas J, Cunningham J, Budinger TF, Harvey-White J. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol. 2000 Jul;164(1):2-14.</citation>
    <PMID>10877910</PMID>
  </reference>
  <reference>
    <citation>Bell P, Moscioni AD, McCarter RJ, Wu D, Gao G, Hoang A, Sanmiguel JC, Sun X, Wivel NA, Raper SE, Furth EE, Batshaw ML, Wilson JM. Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver. Mol Ther. 2006 Jul;14(1):34-44. Epub 2006 May 6.</citation>
    <PMID>16682254</PMID>
  </reference>
  <reference>
    <citation>Binder DK, Rau G, Starr PA. Hemorrhagic complications of microelectrode-guided deep brain stimulation. Stereotact Funct Neurosurg. 2003;80(1-4):28-31.</citation>
    <PMID>14745205</PMID>
  </reference>
  <reference>
    <citation>Bräutigam C, Wevers RA, Hyland K, Sharma RK, Knust A, Hoffman GF. The influence of L-dopa on methylation capacity in aromatic L-amino acid decarboxylase deficiency: biochemical findings in two patients. J Inherit Metab Dis. 2000 Jun;23(4):321-4.</citation>
    <PMID>10896284</PMID>
  </reference>
  <reference>
    <citation>Brument N, Morenweiser R, Blouin V, Toublanc E, Raimbaud I, Chérel Y, Folliot S, Gaden F, Boulanger P, Kroner-Lux G, Moullier P, Rolling F, Salvetti A. A versatile and scalable two-step ion-exchange chromatography process for the purification of recombinant adeno-associated virus serotypes-2 and -5. Mol Ther. 2002 Nov;6(5):678-86.</citation>
    <PMID>12436964</PMID>
  </reference>
  <reference>
    <citation>Cearley CN, Wolfe JH. Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol Ther. 2006 Mar;13(3):528-37. Epub 2006 Jan 18.</citation>
    <PMID>16413228</PMID>
  </reference>
  <reference>
    <citation>Chien YH, Lee NC, Thurberg BL, Chiang SC, Zhang XK, Keutzer J, Huang AC, Wu MH, Huang PH, Tsai FJ, Chen YT, Hwu WL. Pompe disease in infants: improving the prognosis by newborn screening and early treatment. Pediatrics. 2009 Dec;124(6):e1116-25. doi: 10.1542/peds.2008-3667.</citation>
    <PMID>19948615</PMID>
  </reference>
  <reference>
    <citation>Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins RA, VanBrocklin HF, Wright JF, Bankiewicz KS, Aminoff MJ. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology. 2009 Nov 17;73(20):1662-9. doi: 10.1212/WNL.0b013e3181c29356. Epub 2009 Oct 14.</citation>
    <PMID>19828868</PMID>
  </reference>
  <reference>
    <citation>Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med. 1967 Feb 16;276(7):374-9.</citation>
    <PMID>5334614</PMID>
  </reference>
  <reference>
    <citation>Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev. 2008 Oct;21(4):583-93. doi: 10.1128/CMR.00008-08. Review.</citation>
    <PMID>18854481</PMID>
  </reference>
  <reference>
    <citation>Donsante A, Miller DG, Li Y, Vogler C, Brunt EM, Russell DW, Sands MS. AAV vector integration sites in mouse hepatocellular carcinoma. Science. 2007 Jul 27;317(5837):477.</citation>
    <PMID>17656716</PMID>
  </reference>
  <reference>
    <citation>Donsante A, Vogler C, Muzyczka N, Crawford JM, Barker J, Flotte T, Campbell-Thompson M, Daly T, Sands MS. Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther. 2001 Sep;8(17):1343-6.</citation>
    <PMID>11571571</PMID>
  </reference>
  <reference>
    <citation>During MJ, Kaplitt MG, Stern MB, Eidelberg D. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum Gene Ther. 2001 Aug 10;12(12):1589-91.</citation>
    <PMID>11529246</PMID>
  </reference>
  <reference>
    <citation>Eberling JL, Jagust WJ, Christine CW, Starr P, Larson P, Bankiewicz KS, Aminoff MJ. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology. 2008 May 20;70(21):1980-3. doi: 10.1212/01.wnl.0000312381.29287.ff. Epub 2008 Apr 9.</citation>
    <PMID>18401019</PMID>
  </reference>
  <reference>
    <citation>Eslamboli A. Assessment of GDNF in primate models of Parkinson's disease: comparison with human studies. Rev Neurosci. 2005;16(4):303-10. Review.</citation>
    <PMID>16519007</PMID>
  </reference>
  <reference>
    <citation>Fan DS, Ogawa M, Fujimoto KI, Ikeguchi K, Ogasawara Y, Urabe M, Nishizawa M, Nakano I, Yoshida M, Nagatsu I, Ichinose H, Nagatsu T, Kurtzman GJ, Ozawa K. Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors. Hum Gene Ther. 1998 Nov 20;9(17):2527-35.</citation>
    <PMID>9853519</PMID>
  </reference>
  <reference>
    <citation>Ferreira JJ, Rascol O. Prevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson's disease. Curr Opin Neurol. 2000 Aug;13(4):431-6. Review.</citation>
    <PMID>10970061</PMID>
  </reference>
  <reference>
    <citation>Ferreira V, Twisk J, Kwikkers K, Aronica E, Brisson D, Methot J, Petry H, Gaudet D. Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy. Hum Gene Ther. 2014 Mar;25(3):180-8. doi: 10.1089/hum.2013.169. Epub 2014 Feb 28.</citation>
    <PMID>24299335</PMID>
  </reference>
  <reference>
    <citation>Fiumara A, Bräutigam C, Hyland K, Sharma R, Lagae L, Stoltenborg B, Hoffmann GF, Jaeken J, Wevers RA. Aromatic L-amino acid decarboxylase deficiency with hyperdopaminuria. Clinical and laboratory findings in response to different therapies. Neuropediatrics. 2002 Aug;33(4):203-8.</citation>
    <PMID>12368991</PMID>
  </reference>
  <reference>
    <citation>Gaudet D, Méthot J, Déry S, Brisson D, Essiembre C, Tremblay G, Tremblay K, de Wal J, Twisk J, van den Bulk N, Sier-Ferreira V, van Deventer S. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther. 2013 Apr;20(4):361-9. doi: 10.1038/gt.2012.43. Epub 2012 Jun 21.</citation>
    <PMID>22717743</PMID>
  </reference>
  <reference>
    <citation>Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 1977 Jul;36(1):59-74.</citation>
    <PMID>886304</PMID>
  </reference>
  <reference>
    <citation>Grimm D, Kleinschmidt JA. Progress in adeno-associated virus type 2 vector production: promises and prospects for clinical use. Hum Gene Ther. 1999 Oct 10;10(15):2445-50. Review.</citation>
    <PMID>10543610</PMID>
  </reference>
  <reference>
    <citation>Hadaczek P, Eberling JL, Pivirotto P, Bringas J, Forsayeth J, Bankiewicz KS. Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol Ther. 2010 Aug;18(8):1458-61. doi: 10.1038/mt.2010.106. Epub 2010 Jun 8.</citation>
    <PMID>20531394</PMID>
  </reference>
  <reference>
    <citation>Henderson JM, Holloway KL, Gaede SE, Rosenow JM. The application accuracy of a skull-mounted trajectory guide system for image-guided functional neurosurgery. Comput Aided Surg. 2004;9(4):155-60.</citation>
    <PMID>16192055</PMID>
  </reference>
  <reference>
    <citation>Holloway KL, Gaede SE, Starr PA, Rosenow JM, Ramakrishnan V, Henderson JM. Frameless stereotaxy using bone fiducial markers for deep brain stimulation. J Neurosurg. 2005 Sep;103(3):404-13.</citation>
    <PMID>16235670</PMID>
  </reference>
  <reference>
    <citation>Hwu WL, Muramatsu S, Tseng SH, Tzen KY, Lee NC, Chien YH, Snyder RO, Byrne BJ, Tai CH, Wu RM. Gene therapy for aromatic L-amino acid decarboxylase deficiency. Sci Transl Med. 2012 May 16;4(134):134ra61. doi: 10.1126/scitranslmed.3003640.</citation>
    <PMID>22593174</PMID>
  </reference>
  <reference>
    <citation>Hyland K, Clayton PT. Aromatic amino acid decarboxylase deficiency in twins. J Inherit Metab Dis. 1990;13(3):301-4.</citation>
    <PMID>1700191</PMID>
  </reference>
  <reference>
    <citation>Hyland K, Surtees RA, Rodeck C, Clayton PT. Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a new inborn error of neurotransmitter amine synthesis. Neurology. 1992 Oct;42(10):1980-8.</citation>
    <PMID>1357595</PMID>
  </reference>
  <reference>
    <citation>Ichinose H, Kurosawa Y, Titani K, Fujita K, Nagatsu T. Isolation and characterization of a cDNA clone encoding human aromatic L-amino acid decarboxylase. Biochem Biophys Res Commun. 1989 Nov 15;164(3):1024-30.</citation>
    <PMID>2590185</PMID>
  </reference>
  <reference>
    <citation>Janson C, McPhee S, Bilaniuk L, Haselgrove J, Testaiuti M, Freese A, Wang DJ, Shera D, Hurh P, Rupin J, Saslow E, Goldfarb O, Goldberg M, Larijani G, Sharrar W, Liouterman L, Camp A, Kolodny E, Samulski J, Leone P. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum Gene Ther. 2002 Jul 20;13(11):1391-412.</citation>
    <PMID>12162821</PMID>
  </reference>
  <reference>
    <citation>Kang UJ, Fisher LJ, Joh TH, O'Malley KL, Gage FH. Regulation of dopamine production by genetically modified primary fibroblasts. J Neurosci. 1993 Dec;13(12):5203-11.</citation>
    <PMID>7902865</PMID>
  </reference>
  <reference>
    <citation>Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D, During MJ. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet. 2007 Jun 23;369(9579):2097-105.</citation>
    <PMID>17586305</PMID>
  </reference>
  <reference>
    <citation>Kay MA. AAV vectors and tumorigenicity. Nat Biotechnol. 2007 Oct;25(10):1111-3.</citation>
    <PMID>17921994</PMID>
  </reference>
  <reference>
    <citation>Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A, Glader B, Chew AJ, Tai SJ, Herzog RW, Arruda V, Johnson F, Scallan C, Skarsgard E, Flake AW, High KA. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet. 2000 Mar;24(3):257-61.</citation>
    <PMID>10700178</PMID>
  </reference>
  <reference>
    <citation>Korenke GC, Christen HJ, Hyland K, Hunneman DH, Hanefeld F. Aromatic L-amino acid decarboxylase deficiency: an extrapyramidal movement disorder with oculogyric crises. Eur J Paediatr Neurol. 1997;1(2-3):67-71.</citation>
    <PMID>10728198</PMID>
  </reference>
  <reference>
    <citation>Lee NC, Chien YH, Hu MH, Liu WS, Chen PW, Wang WH, Tzen KY, Byrne BJ, Hwu WL. Treatment of congenital neurotransmitter deficiencies by intracerebral ventricular injection of an adeno-associated virus serotype 9 vector. Hum Gene Ther. 2014 Mar;25(3):189-98. doi: 10.1089/hum.2013.170. Epub 2014 Jan 7.</citation>
    <PMID>24251946</PMID>
  </reference>
  <reference>
    <citation>Lee NC, Shieh YD, Chien YH, Tzen KY, Yu IS, Chen PW, Hu MH, Hu MK, Muramatsu S, Ichinose H, Hwu WL. Regulation of the dopaminergic system in a murine model of aromatic L-amino acid decarboxylase deficiency. Neurobiol Dis. 2013 Apr;52:177-90. doi: 10.1016/j.nbd.2012.12.005. Epub 2012 Dec 26.</citation>
    <PMID>23275025</PMID>
  </reference>
  <reference>
    <citation>Lee WY, Chang JW, Nemeth NL, Kang UJ. Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase enhance dopamine delivery after L-3, 4-dihydroxyphenylalanine administration in Parkinsonian rats. J Neurosci. 1999 Apr 15;19(8):3266-74.</citation>
    <PMID>10191339</PMID>
  </reference>
  <reference>
    <citation>Leff SE, Spratt SK, Snyder RO, Mandel RJ. Long-term restoration of striatal L-aromatic amino acid decarboxylase activity using recombinant adeno-associated viral vector gene transfer in a rodent model of Parkinson's disease. Neuroscience. 1999;92(1):185-96.</citation>
    <PMID>10392841</PMID>
  </reference>
  <reference>
    <citation>Limousin P, Martinez-Torres I. Deep brain stimulation for Parkinson's disease. Neurotherapeutics. 2008 Apr;5(2):309-19. doi: 10.1016/j.nurt.2008.01.006. Review.</citation>
    <PMID>18394572</PMID>
  </reference>
  <reference>
    <citation>Maller A, Hyland K, Milstien S, Biaggioni I, Butler IJ. Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a second family. J Child Neurol. 1997 Sep;12(6):349-54.</citation>
    <PMID>9309516</PMID>
  </reference>
  <reference>
    <citation>Matsushita T, Elliger S, Elliger C, Podsakoff G, Villarreal L, Kurtzman GJ, Iwaki Y, Colosi P. Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther. 1998 Jul;5(7):938-45.</citation>
    <PMID>9813665</PMID>
  </reference>
  <reference>
    <citation>McCarty DM, Young SM Jr, Samulski RJ. Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet. 2004;38:819-45. Review.</citation>
    <PMID>15568995</PMID>
  </reference>
  <reference>
    <citation>Mittermeyer G, Christine CW, Rosenbluth KH, Baker SL, Starr P, Larson P, Kaplan PL, Forsayeth J, Aminoff MJ, Bankiewicz KS. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. Hum Gene Ther. 2012 Apr;23(4):377-81. doi: 10.1089/hum.2011.220. Epub 2012 Apr 10.</citation>
    <PMID>22424171</PMID>
  </reference>
  <reference>
    <citation>Muramatsu S, Fujimoto K, Ikeguchi K, Shizuma N, Kawasaki K, Ono F, Shen Y, Wang L, Mizukami H, Kume A, Matsumura M, Nagatsu I, Urano F, Ichinose H, Nagatsu T, Terao K, Nakano I, Ozawa K. Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum Gene Ther. 2002 Feb 10;13(3):345-54.</citation>
    <PMID>11860702</PMID>
  </reference>
  <reference>
    <citation>Muramatsu S, Fujimoto K, Kato S, Mizukami H, Asari S, Ikeguchi K, Kawakami T, Urabe M, Kume A, Sato T, Watanabe E, Ozawa K, Nakano I. A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol Ther. 2010 Sep;18(9):1731-5. doi: 10.1038/mt.2010.135. Epub 2010 Jul 6.</citation>
    <PMID>20606642</PMID>
  </reference>
  <reference>
    <citation>Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J, Della Peruta M, Lheriteau E, Patel N, Raj D, Riddell A, Pie J, Rangarajan S, Bevan D, Recht M, Shen YM, Halka KG, Basner-Tschakarjan E, Mingozzi F, High KA, Allay J, Kay MA, Ng CY, Zhou J, Cancio M, Morton CL, Gray JT, Srivastava D, Nienhuis AW, Davidoff AM. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014 Nov 20;371(21):1994-2004. doi: 10.1056/NEJMoa1407309.</citation>
    <PMID>25409372</PMID>
  </reference>
  <reference>
    <citation>Ozawa K, Fan DS, Shen Y, Muramatsu S, Fujimoto K, Ikeguchi K, Ogawa M, Urabe M, Kume A, Nakano I. Gene therapy of Parkinson's disease using adeno-associated virus (AAV) vectors. J Neural Transm Suppl. 2000;(58):181-91. Review.</citation>
    <PMID>11128607</PMID>
  </reference>
  <reference>
    <citation>Peterson AL, Nutt JG. Treatment of Parkinson's disease with trophic factors. Neurotherapeutics. 2008 Apr;5(2):270-80. doi: 10.1016/j.nurt.2008.02.003. Review.</citation>
    <PMID>18394569</PMID>
  </reference>
  <reference>
    <citation>Pons R, Ford B, Chiriboga CA, Clayton PT, Hinton V, Hyland K, Sharma R, De Vivo DC. Aromatic L-amino acid decarboxylase deficiency: clinical features, treatment, and prognosis. Neurology. 2004 Apr 13;62(7):1058-65. Review.</citation>
    <PMID>15079002</PMID>
  </reference>
  <reference>
    <citation>Russell DW, Alexander IE, Miller AD. DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors. Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5719-23.</citation>
    <PMID>7777575</PMID>
  </reference>
  <reference>
    <citation>Swoboda KJ, Hyland K, Goldstein DS, Kuban KC, Arnold LA, Holmes CS, Levy HL. Clinical and therapeutic observations in aromatic L-amino acid decarboxylase deficiency. Neurology. 1999 Oct 12;53(6):1205-11.</citation>
    <PMID>10522874</PMID>
  </reference>
  <reference>
    <citation>Swoboda KJ, Saul JP, McKenna CE, Speller NB, Hyland K. Aromatic L-amino acid decarboxylase deficiency: overview of clinical features and outcomes. Ann Neurol. 2003;54 Suppl 6:S49-55.</citation>
    <PMID>12891654</PMID>
  </reference>
  <reference>
    <citation>Sydow O. Parkinson's disease: recent development in therapies for advanced disease with a focus on deep brain stimulation (DBS) and duodenal levodopa infusion. FEBS J. 2008 Apr;275(7):1370-6. doi: 10.1111/j.1742-4658.2008.06295.x. Epub 2008 Feb 12. Review.</citation>
    <PMID>18279380</PMID>
  </reference>
  <reference>
    <citation>Tardieu M, Zérah M, Husson B, de Bournonville S, Deiva K, Adamsbaum C, Vincent F, Hocquemiller M, Broissand C, Furlan V, Ballabio A, Fraldi A, Crystal RG, Baugnon T, Roujeau T, Heard JM, Danos O. Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial. Hum Gene Ther. 2014 Jun;25(6):506-16. doi: 10.1089/hum.2013.238. Epub 2014 May 5.</citation>
    <PMID>24524415</PMID>
  </reference>
  <reference>
    <citation>Tay SK, Poh KS, Hyland K, Pang YW, Ong HT, Low PS, Goh DL. Unusually mild phenotype of AADC deficiency in 2 siblings. Mol Genet Metab. 2007 Aug;91(4):374-8. Epub 2007 May 29.</citation>
    <PMID>17533144</PMID>
  </reference>
  <reference>
    <citation>Wagner JA, Moran ML, Messner AH, Daifuku R, Conrad CK, Reynolds T, Guggino WB, Moss RB, Carter BJ, Wine JJ, Flotte TR, Gardner P. A phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis. Hum Gene Ther. 1998 Apr 10;9(6):889-909.</citation>
    <PMID>9581911</PMID>
  </reference>
  <reference>
    <citation>Warren Olanow C, Bartus RT, Baumann TL, Factor S, Boulis N, Stacy M, Turner DA, Marks W, Larson P, Starr PA, Jankovic J, Simpson R, Watts R, Guthrie B, Poston K, Henderson JM, Stern M, Baltuch G, Goetz CG, Herzog C, Kordower JH, Alterman R, Lozano AM, Lang AE. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Ann Neurol. 2015 Aug;78(2):248-57. doi: 10.1002/ana.24436. Epub 2015 Jun 10.</citation>
    <PMID>26061140</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2016</study_first_submitted>
  <study_first_submitted_qc>October 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2016</study_first_posted>
  <last_update_submitted>October 18, 2017</last_update_submitted>
  <last_update_submitted_qc>October 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aromatic L-amino acid decarboxylase (AADC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amino Acid Metabolism, Inborn Errors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dopa Decarboxylase</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

